OLYS Pharma
OLYS Pharma develops topical/transdermal treatments for chronic inflammatory pain conditions by modulating neurogenic inflammation.
OLYS Pharma targets treatments for painful chronic inflammatory conditions through topical/transdermal modulation of pain, neurotransmission, and innate immune response to break the pro-inflammatory cycle of neurogenic inflammation. The research includes modulation of dorsal root ganglion (DRG) activity to treat pain and low-grade inflammation in organs while preventing brain remodeling.
Key People
Philippe Van Wesepoel - Co-fondateur- Jean François Plucker - Co-fondateur